Showing 2826 results for "hemophilia"

The privilege of choice in the treatment of hemophilia

When I was diagnosed with hemophilia B and von Willebrand disease as a child, there were no choices in terms of treatment strategy. Treatment for me came in the form of intravenous blood products administered only in the hospital. Fast-forward to today, and I’m fortunate to have options…

Hemgenix hemophilia B gene therapy reimbursable in Germany

The cost of the one-time hemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) will now be covered for eligible patients in Germany through the country’s public healthcare system. This comes through a reimbursement price agreement between developer CSL Behring and GKV-Spitzenverband, the German National Association of Statutory Health…

Recombinate (antihemophilic factor recombinant) for hemophilia

Recombinate (antihemophilic factor recombinant) was a recombinant (lab-made) clotting factor VIII (FVIII) concentrate that was approved to prevent and control bleeds, including those occurring during surgery, in children and adults with hemophilia A. It was administered via intravenous, or into-the-vein, injection.

Takeda to discontinue Hemofil M, Recombinate for hemophilia A

Takeda Pharmaceuticals has decided to discontinue Hemofil M (human antihemophilic factor) and Recombinate (recombinant antihemophilic factor), both of which are approved as replacement therapies to prevent and control bleeding episodes in children and adults with hemophilia A. “This was not a decision we made lightly,” Anthea Cherednichenko,…